Form 4: NewAmsterdam Pharma Co N.V. Executive Exercises Options, Sells Shares to Cover Tax Obligations
SEC Form 4
Johannes Jacob Pieter Kastelein, Chief Scientific Officer of NewAmsterdam Pharma Co N.V., exercised options and sold shares to satisfy tax liabilities, as detailed in a recent SEC filing.
Summary
- Johannes Jacob Pieter Kastelein, the Chief Scientific Officer of NewAmsterdam Pharma Co N.V., executed transactions involving the company's ordinary shares on March 26, 2024.
- Kastelein exercised options to acquire 201,673 ordinary shares.
- Simultaneously, 11,197 shares were withheld to cover the exercise price of the options.
- Kastelein sold 190,476 shares at a price of $21.50 per share.
- These transactions were conducted to satisfy certain tax liabilities, utilizing an exemption within a lock-up agreement dated February 12, 2024.
- Following these transactions, Kastelein indirectly holds 190,476 ordinary shares and options for 970,229 shares through Futurum B.V. and NAP PoolCo B.V., maintaining sole voting and investment control.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports transactions. The sale of shares could be seen as slightly negative, but the exercise of options is generally viewed as positive.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. This filing provides transparency into the transactions of a key executive at NewAmsterdam Pharma, allowing investors to track insider activity.
Stakeholder Impact
- The share sale could have a minor impact on shareholders due to the increased supply of shares in the market.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| July 6, 2021 | Original option grant date which was later cancelled. |
| November 22, 2022 | Option was granted to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. |
| February 12, 2024 | Date of the lock-up agreement under which the share sale exemption was granted. |
| March 26, 2024 | Date of the option exercise and share sale transactions. |
| March 27, 2024 | Date of the SEC filing. |
| July 06, 2031 | Expiration date of the option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.